Norgen Biotek Corporation

Thorold, Canada

Norgen Biotek Corporation

Thorold, Canada
SEARCH FILTERS
Time filter
Source Type

First, Norgen has launched the new Small RNA Library Prep Kit for Illumina.  This kit consists of all the reagents and components required to generate small RNA libraries to be used for next-generation sequencing on an Illumina platform. This kit has been optimized for low input RNA (0.5-1ng), especially from bodily fluids and liquid biopsy samples such as plasma, serum, blood, cerebral spinal fluid (CSF), urine and exosomes. The simple and rapid workflow allows for the library to be prepared in less than 5 hours, with no gel purification required for selected types of samples. Norgen has also launched complementary products for Small RNA Library construction including NGS-compatible cel-miR-39 spike-in as well as the NGS Library Quantification Kit (for Small RNA-Seq). In addition, Norgen is also pleased to offer a wide range of NGS services to the scientific community.  These include isolation services, library preparation, sequencing and bioinformatics. Norgen is working with many clients, and has extensive experience working with low concentration clinical samples. Norgen's state-of-the-art facility employs multiple Illumina sequencing platforms including MiSeq and NextSeq 500, allowing a full sequencing menu including Small RNA-seq, RNA-seq, 16S Metagenomics, targeted (DNA/RNA) sequencing, exome sequencing and whole genome sequencing. "This new NGS portfolio represents a very exciting addition to our line of high quality products and service offerings.  This focus on NGS is a natural expansion of our leading position in liquid biopsies and low input sample prep.  The addition of different Illumina platforms allows us to combine our sample prep expertise with our ISO-certified CLIA-equivalent service offerings" said Dr. Haj-Ahmad, President & CEO of Norgen Biotek. Norgen Biotek Corp., an ISO 15189:2007, ISO 13485:2003 and ISO 9001:2008 registered company, is a privately-held Canadian biotech company committed to providing innovative products and services to the life sciences and pharmaceutical industry. Norgen is applying its proprietary technologies to develop best-in-class products for the purification of NA and proteins, as well as NGS. Currently, Norgen is focused on advancements in tools for companion diagnostic and personalized medicine, as well as developing diagnostics for resources limited areas, point-of-care and home use. Detailed information about the company is available at www.norgenbiotek.com or contact Dr. Yousef Haj-Ahmad, President & CEO, Norgen Biotek. Phone: (905) 227-8848, Fax: (905) 227-1061, Email: yha@norgenbiotek.com.


Hamzeh-Mivehroud M.,Tabriz University of Medical Sciences | Mahmoudpour A.,Tabriz University of Medical Sciences | Mahmoudpour A.,Norgen Biotek Corporation | Dastmalchi S.,Tabriz University of Medical Sciences
Chemical Biology and Drug Design | Year: 2012

Peptide phage display, a powerful method for ligand identification, was used to identify new peptide ligands for epidermal growth factor receptor. A-431 cells expressing epidermal growth factor receptor were used as the matrix in a cell-based subtractive biopanning approach using a 7-mer peptide displaying phage library. Two novel peptide ligands were identified and tested for their affinities and functional effects on epidermal growth factor receptor. The identified peptides were able to inhibit the epidermal growth factor-induced phosphorylation of epidermal growth factor receptor in a concentration-dependent manner. The results of affinity binding experiments showed that the natural ligand, that is epidermal growth factor, was able to inhibit competitively the binding of peptide-bearing phage to epidermal growth factor receptor expressing A-431 cells. Molecular modeling studies were used to calculate the free energies for the binding of peptides to the receptor-binding site as well as proposing the interaction modes for this binding. The calculated values for the binding energies were found to be similar to our experimental data and those of previously reported studies. © 2011 John Wiley & Sons A/S.


Simkin M.,Brock University | Simkin M.,Norgen Biotek Corporation | Abdalla M.,Norgen Biotek Corporation | El-Mogy M.,Norgen Biotek Corporation | And 2 more authors.
Epigenomics | Year: 2012

TP53 is a tumor-suppressor gene coding for p53, a protein responsible for cell-cycle arrest and DNA repair. Smoking has been demonstrated to lead to the methylation of tumor-suppressor genes in noncancerous lung biopsy tissues of smokers, and in bodily fluids, promoter hypermethylation occurs very early in the progression of cancer. Thus, DNA methylation changes may be initiated long before cells become cancerous. As this association has never been explored in young, healthy individuals, we decided to look at DNA isolated from urine and saliva samples taken from young male and female smoking and nonsmoking participants. While p53 methylation was not found in any of the samples tested, differences in DNA concentration between the two groups may shed light on the timing of epigenetic alterations, as well as better explain why the negative impact of smoking is not often found in young, healthy adults. © Future Medicine Ltd.


Provided is a nucleic acid preservative comprising at least one reducing agent, at least one chaotropic substance, at least one polyamine substance and at least one chelating agent and uses thereof, and a method for the preservation of nucleic acids in a biological sample. Further provided are kits for use in the preservation of nucleic acids in a biological sample, and more particularly, a blood sample.


Patent
Norgen Biotek Corporation | Date: 2011-07-22

The present invention provides a device for the concentration of one or more target analytes contained in a urine sample. The device comprises a tube comprising an upper portion defining an opening for receiving the urine sample and a lower tapered portion terminating in collection reservoir. The tube contains a predetermined amount of a particulate binding agent which specifically binds the one or more target analytes and of a predetermined amount of a binding buffer. The device comprises means for seating the opening of the tube. The present invention further provides methods and kits for concentrating one or more target analytes in murine sample.


Disclosed are microRNA biomarkers and use thereof for screening and diagnosis of prostate cancer and benign prostatic hyperplasia. This invention provides a method for screening for prostate cancer in a subject involving the steps of: (a) assaying the miRNA expression level in a test sample from the subject to be screened for prostate cancer; (b) comparing the assayed miRNA expression level of the subject to the miRNA expression level in a normal sample providing a control relative to the test sample of the subject; and (c) computing the differential expression of the miRNA from the subject, wherein the over-expression of miR-1825 or under the expression of miR-484 is indicative of prostate cancer. In another aspect, provided is a method for screening for benign prostatic hyperplasia in a subject involving the steps of: (a) assaying the miRNA expression level in a test sample from the subject to be screened for benign prostatic hyperplasia; (b) comparing the assayed miRNA expression level of the subject to the miRNA expression level in a normal sample providing a control relative to the test sample of the subject; and (c) computing the differential expression of the miRNA from the subject, wherein the under expression of miR-498 is indicative of benign prostatic hyperplasia.


Patent
Norgen Biotek Corporation | Date: 2016-05-06

Disclosed is a method for the isolation of extracellular vesicles, including exosomes, from a liquid sample, the method comprising the steps of: adjusting the pH of a liquid sample comprising extracellular vesicles to a preselected, binding pH; contacting the liquid sample with silicon carbide, wherein at the preselected, binding pH, the extracellular vesicles bind to the silicon carbide; and eluting the bound extracellular vesicles from the silicon carbide. The liquid samples can comprise bodily fluids. Further disclosed is a method for producing a liquid sample, substantially depleted of extracellular vesicles, including exosomes.


Patent
Norgen Biotek Corporation | Date: 2016-07-19

Provided are methods and columns employing a solid support comprising silica and silicon carbide for the isolation and purification of nucleic acids, and in particular, the isolation and purification of both high and low molecular weight RNA.


Patent
Norgen Biotek Corporation | Date: 2014-04-30

The present invention provides a device for the concentration of one or more target analytes contained in a urine sample. The device comprises a tube comprising an upper portion defining an opening for receiving the urine sample and a lower tapered portion terminating in a collection reservoir. The tube contains a predetermined amount of a particulate binding agent which specifically binds the one or more target analytes and of a predetermined amount of a binding buffer. The device comprises means for sealing the opening of the tube. The present invention further provides methods and kits for concentrating one or more target analytes in a urine sample.


PubMed | University of Arkansas for Medical Sciences and Norgen Biotek Corporation
Type: | Journal: International journal of nephrology | Year: 2016

Diabetic nephropathy (DN) and diabetic retinopathy (DR) are major complications of type 1 and type 2 diabetes. DN and DR are mainly caused by injury to the perivascular supporting cells, the mesangial cells within the glomerulus, and the pericytes in the retina. The genes and molecular mechanisms predisposing retinal and glomerular pericytes to diabetic injury are poorly characterized. In this study, the genetic deletion of proteasome activator genes, PA28

Loading Norgen Biotek Corporation collaborators
Loading Norgen Biotek Corporation collaborators